Stockreport

Ovid Therapeutics: OV329 Promising For Neuronal Excitability In Neurological Disorders [Seeking Alpha]

Ovid Therapeutics Inc.  (OVID) 
Last ovid therapeutics inc. earnings: 3/11 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.ovidrx.com
PDF Pipeline includes KCC2 activators OV350 (IV) and OV4071 (oral) for neurological and psychiatric disorders, with key data and regulatory milestones expected through 2026 [Read more]